Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Hepatic Artery Flow and Propranolol Metabolism in Perfused Cirrhotic Rat Liver

Loading...
Thumbnail Image

Date

Authors

Le Couteur, D
Hickey, Haruyo
Harvey, Peta
Gready, Jill
McLean, Allan J

Journal Title

Journal ISSN

Volume Title

Publisher

American Society for Pharmacology and Experimental Therapeutics

Abstract

The oxygen limitation theory states that capillarization of the sinusoidal endothelium in cirrhosis impairs hepatocellular oxygen uptake manifesting as a reduction in oxygen-dependent enzyme activity including phase I drug metabolism. The hepatic artery supplies highly oxygenated blood to the liver. Therefore, we tested whether augmentation of hepatic arterial blood flow could improve hepatic oxygenation and function in cirrhosis. Rats were treated with carbon tetrachloride and phenobarbitone to induce hepatic cirrhosis or fibrosis. We used a bivascular rat liver perfusion model to examine the effects of increased hepatic artery flow on propranolol clearance and oxygen consumption. Each liver was perfused at three hepatic artery flow rates, 1 to 3, 4 to 6, and 7 to 9 ml/min with a constant portal venous flow of 7 to 9 ml/min. Increasing the hepatic artery flow led to improvement in propranolol clearance in control (n = 7, P < .001), fibrotic (n = 8, P < .001), and cirrhotic (n = 6, P < .001) livers. Intrinsic clearance of propranolol increased only in the cirrhotic livers (P = .01), indicating an improvement in enzyme activity. Regression analysis indicated that this improvement was mediated by change in oxygen delivery alone (P = .001). The results confirm that propranolol metabolizing enzyme activity in cirrhosis can be improved by increasing oxygen delivery by increasing hepatic arterial blood flow. These findings suggest that increasing hepatic arterial blood flow may be an important therapeutic strategy for improving global liver function in cirrhosis.

Description

Citation

Source

Journal of Pharmacology and Experimental Therapeutics

Book Title

Entity type

Access Statement

License Rights

DOI

Restricted until

2037-12-31